PRGO - Perrigo Company PLC Debt to Book Capitalization Ratio

Graphic logo of Perrigo Company PLC (PRGO)

This chart illustrates that the market value of Perrigo Company plc (PRGO) on the GURU.Markets platform is 1.30. Management is currently restructuring its strategy to focus on health products and reduce debt. Distribution relies on accessible warehouse logistics, ensuring uninterrupted supplies to pharmacies. Meanwhile, the development of private labels allows the company to lower production costs and maintain stable business profitability.

PRGO (Perrigo Corp) Debt to Book Value history from 07/04/2022 to 10/27/2026
Core merchandise of Perrigo Company

This indicator measures the extent to which all liabilities are covered by net assets, allowing for an assessment of financial stability and debt load risk during business recovery. An analysis of the debt-to-equity ratio for Perrigo Company plc (PRGO) confirms its status as a defensive asset, as demand for affordable Private Label products during a recession stabilizes the capital base, minimizing default risks for the investor.

Competitors of Perrigo Company plc

Debts to Book Capitalization HLN (Haleon plc)|kenvue.com - Debts to Book Capitalization|Debt to Book Capitalization Ratio Verona Pharma (VRNA)|MENS: Debt to Net Assets Ratio|LGND (Ligand Pharma) - Debt to Book Capitalization Ratio|Amneal Corp (AMRX) - Debt to Book Value|ALVO (Alvotech) - Debts to Book Capitalization|Debts to Book Capitalization liquidia.com (LQDA)|Galapagos (GLPG) - Debt to Book Value|Debt to Net Assets Ratio ANIP (ANI Pharmaceuticals Inc)|MNKD: Debt to Book Capitalization Ratio|AMPH - Debts to Book Value|Debt to Book Value Pacira BioSciences PCRX|SPRY - Debt to Book Capital|Debts to Book Capitalization Theravance Biopharma, Inc. TBPH|Aquestive Therapeutics Inc (AQST) - Debt to Net Assets Ratio|Debts to Book Capitalization SCPH (scPharmaceuticals, Inc.)|Debts to Book Value TECX|Tonix Pharmaceuticals (TNXP) - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio SXTC (sxtchina.com)|Eupraxia Pharmaceuticals Inc. (EPRX) - Debt to Book Capitalization Ratio|Debts to Book Capitalization Ratio BioHarvest Sciences, Inc. BHST|EXOZ (Invizyne Technologies, Inc.) - Debts to Book Capitalization|ORMP: Debts to Book Value|Debt to Book Capitalization Ratio enterabio.com ENTX|HYFT (ipatherapeutics.com) - Debt to Net Assets Ratio|ABVC - Debt to Book Capitalization Ratio|Debt to Net Assets Ratio Cumberland Pharmaceuticals Inc|QNTM (Quantum BioPharma Limited) - Debts to Book Capitalization|Debts to Net Assets FibroGen Corporation (FGEN)|TELO (Telomir Pharmaceuticals) - Debts to Book Capitalization|Rani Therapeutics Holdings - Debt to Net Assets|SNYR (Synergy CHC Corporation) - Debt to Book Capitalization Ratio|Rallybio Corporation (RLYB) - Debts to Book Value|Debt to Book Value lexariabioscience.com LEXX|Pulmatrix Corporation (PULM) - Debt to Net Assets Ratio|Debts to Book Capitalization PTHL|Debt to Book Value APM|Lyra Therapeutics - Debt to Book Capitalization Ratio|Debts to Book Value IBO (Impact BioMedical, Inc.)|TNF Pharmaceuticals, Inc. - Debt to Book Capitalization Ratio|cbdMD Inc. - Debt to Book Value|Debt to Book Capitalization Ratio PainReform Ltd.|CYTO - Debts to Book Capitalization Ratio|LIPO: Debts to Book Capitalization|OPTN (OptiNose Inc) - Debts to Book Capitalization|Debt to Book Capitalization Ratio Pieris (PIRS)|Debt to Book Value Ratio Procaps Group Corp (PROC)|Petros Pharmaceuticals - Debt to Book Value|Debts to Book Value qlsyy.net QLI|Debt to Book Value ACELYRIN|TFF Pharmaceuticals Inc. - Debt to Net Assets Ratio